文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

静脉伊马替尼治疗COVID-19 ARDS的疗效与安全性:一项随机双盲安慰剂对照临床试验

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.
PubMed 文献 · Crit Care · 2023-06-08
一句话结论静脉伊马替尼未减少有创通气COVID-19 ARDS患者的肺水肿或改善临床结局,但高IL-6、TNFR1、SP-D亚组肺水肿下降。

这项多中心随机双盲安慰剂对照试验纳入66例有创通气的中重度COVID-19 ARDS患者,随机接受静脉伊马替尼200 mg每日两次(最多7天)或安慰剂。主要终点第1至4天肺血管外肺水指数变化(∆EVLWi)组间无差异(0.19 ml/kg,95% CI -3.16至2.77,p=0.89)。伊马替尼未影响有创通气时长(p=0.29)、无呼吸机天数(p=0.29)或28天死亡率(p=0.79),耐受性良好且似安全。在高IL-6、TNFR1和SP-D水平亚组(n=20)中,伊马替尼显著降低每治疗日EVLWi(-1.17 ml/kg,95% CI -1.87至-0.44)。

要点

  • 静脉伊马替尼200 mg每日两次最多7天,未降低有创通气COVID-19 ARDS患者第1至4天∆EVLWi(0.19 ml/kg,95% CI -3.16至2.77,p=0.89)。
  • 伊马替尼未改善有创通气时长(p=0.29)、无呼吸机天数(p=0.29)或28天死亡率(p=0.79)。
  • 静脉伊马替尼耐受性良好且似安全。
  • 高IL-6、TNFR1和SP-D水平亚组(n=20)中,伊马替尼显著降低每治疗日EVLWi(-1.17 ml/kg,95% CI -1.87至-0.44)。
  • 作者认为该试验不支持在一般COVID-19 ARDS人群中使用伊马替尼,亚组结果凸显预测性富集在ARDS试验中的潜在价值。

适用人群与场景

  • 有创通气的中重度COVID-19 ARDS患者,随机接受静脉伊马替尼或安慰剂。

处置流程与药物剂量

  • 静脉伊马替尼200 mg,每日两次,最多7天。

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照试验,66例患者随机至伊马替尼组(n=33)或安慰剂组(n=33)。
  • 主要终点第1至4天∆EVLWi组间无差异(0.19 ml/kg,95% CI -3.16至2.77,p=0.89)。
  • 伊马替尼未影响有创通气时长(p=0.29)、无呼吸机天数(p=0.29)或28天死亡率(p=0.79)。
  • 静脉伊马替尼耐受性良好且似安全。
  • 高IL-6、TNFR1和SP-D水平亚组(n=20)中,伊马替尼显著降低每治疗日EVLWi(-1.17 ml/kg,95% CI -1.87至-0.44)。

证据类型、等级与局限

  • 随机、双盲、安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该试验不支持在一般COVID-19 ARDS人群中使用伊马替尼。
  • 作者认为高IL-6、TNFR1和SP-D水平亚组的肺水肿改善结果凸显预测性富集在ARDS试验中的潜在价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: A hallmark of acute respiratory distress syndrome (ARDS) is hypoxaemic respiratory failure due to pulmonary vascular hyperpermeability. The tyrosine kinase inhibitor imatinib reversed pulmonary capillary leak in preclinical studies and improved clinical outcomes in hospitalized COVID-19 patients. We investigated the effect of intravenous (IV) imatinib on pulmonary edema in COVID-19 ARDS.

METHODS: This was a multicenter, randomized, double-blind, placebo-controlled trial. Invasively ventilated patients with moderate-to-severe COVID-19 ARDS were randomized to 200 mg IV imatinib or placebo twice daily for a maximum of seven days. The primary outcome was the change in extravascular lung water index (∆EVLWi) between days 1 and 4. Secondary outcomes included safety, duration of invasive ventilation, ventilator-free days (VFD) and 28-day mortality. Posthoc analyses were performed in previously identified biological subphenotypes.

RESULTS: 66 patients were randomized to imatinib (n = 33) or placebo (n = 33). There was no difference in ∆EVLWi between the groups (0.19 ml/kg, 95% CI - 3.16 to 2.77, p = 0.89). Imatinib treatment did not affect duration of invasive ventilation (p = 0.29), VFD (p = 0.29) or 28-day mortality (p = 0.79). IV imatinib was well-tolerated and appeared safe. In a subgroup of patients characterized by high IL-6, TNFR1 and SP-D levels (n = 20), imatinib significantly decreased EVLWi per treatment day (- 1.17 ml/kg, 95% CI - 1.87 to - 0.44).

CONCLUSIONS: IV imatinib did not reduce pulmonary edema or improve clinical outcomes in invasively ventilated COVID-19 patients. While this trial does not support the use of imatinib in the general COVID-19 ARDS population, imatinib reduced pulmonary edema in a subgroup of patients, underscoring the potential value of predictive enrichment in ARDS trials. Trial registration NCT04794088 , registered 11 March 2021. European Clinical Trials Database (EudraCT number: 2020-005447-23).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Atmowihardjo LN, Schippers JR, Duijvelaar E, et al. Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial. Crit Care. 2023. PMID: 37291677. doi:10.1186/s13054-023-04516-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。